Job Description
This is for a 12-week internship position from June August 2021.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. We work together to bring life-changing therapies to patients every day.
We are currently seeking MBA summer interns across our Global Product Strategy and Commercialization (GPS&C) function. This group includes key areas of our global commercial organization including Product Development and Commercialization (PDC), Customer Excellence and Operations (CE&O), and Global Value & Access (V&A).
MBA Interns will be responsible for completing project(s) that deal with strategic business issues. These project(s) will provide the Interns exposure to business leaders and cross-functional areas. Participants will be expected to demonstrate in-depth understanding of the critical issues, decision-making, and project management skills. The participant will be required to work independently as well as in a team environment. Assignments will be based on business needs as well as candidate experience and interest.
Intern assignments may be available within any of the following areas:
Product Development and Commercialization (PDC)
The PDC teams develop and realize the worldwide strategy for Biogens products from Phase III initiation, through pre-launch planning, launch and commercialization, and ongoing life cycle management. We manage Biogens global brands, supporting our existing portfolio of therapies as well as products in late-stage clinical development. We work from a deep understanding of the science behind our therapies and the disease areas they treat.
Customer Excellence and Operations (CE&O)
Customer Excellence and Operations is at the intersection of data sciences and commercial investment decision-making. We collaborate with colleagues across the GPS&C organization to optimize business choices and product strategy. Biogen employees within Customer Excellence & Operations work in a wide array of different fields and centers of excellence, including: Customer & Market Insights (CMI), Multichannel Excellence (MCE), Data Sciences, and Forecasting.
Value & Access (V&A)
Global Value & Access brings together Economics, Science and Medicine to leverage the clinical and economic value of Biogens commitment to neuroscience. In a complex and ever-evolving global reimbursement landscape, the V&A team is responsible for staying abreast of the market trends and optimizing the value of Biogens assets and delivery of product to patients.
Key responsibilities will vary based on the interns project, but examples may include:
* Assess competitive landscape and ensure readiness for key events
* Supporting development of pricing and access strategies
* Create framework to evaluate commercial viability of early stage or external assets
* Develop marketing tools for use by Biogens affiliates around the world
* Assess opportunities to enhance product profile through life cycle management
* Utilize data to create marketing mix models
Qualifications
* A minimum of 3 years relevant professional experience required.
* Demonstrated cycles of success in a professional business environment required.
* Strong problem solving, organizational, communication and analytical skills are required.
* Experience influencing through the matrix, leading cross functional and cross geography teams
* Legally authorized to work in the United States without the need for sponsorship now or in the future is required.
Skills & behaviors:
* Ability to drive results in a highly matrixed organization without direct authority
* Establish effective trust-based relationships with internal and external stakeholders from different functions and seniority levels; highly collaborative
* Ability to work effectively prioritize work; strong project management skills
* Highly independent/autonomous and self-motivated - demonstrated ability to thrive in less well-defined work environments and demonstrates attitude of ownership
* Flexibility - ability to adapt to changing priorities and evolving needs
* Strong leadership, communication and presentation skills, both oral and written, including ability to synthesize information for senior management; communicates proactively in clear, timely and open manner; raises issues in a constructive manner
Education:
* B.A./B.Sc. required; in related field preferred (business, science, technology)
* Enrolled in an accredited MBA Program with graduation planned for 2022.
* Concentration in Marketing, General Management, and/or Healthcare Management is preferred.
Additional Information
All your information will be kept confidential according to EEO guidelines.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.